TY  - JOUR
AU  - Rojo, Federico
AU  - Conde Gallego, Esther
AU  - Nadal, Ernest
PY  - 2022
DO  - 10.1186/s12885-022-09397-4
SN  - 1471-2407
UR  - https://hdl.handle.net/20.500.14352/116528
T2  - BMC Cancer
AB  - BackgroundDetection of the ROS1 rearrangement is mandatory in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to allow targeted therapy with specific inhibitors. However, in Spanish clinical practice ROS1 determination is not...
LA  - eng
PB  - Springer
KW  - C-ros oncogene 1
KW  - Non-small cell lung cancer
KW  - Molecular testing
KW  - Biomarker guided selection
KW  - Cost-effectiveness analysis
TI  - Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain
TY  - journal article
VL  - 22
ER  -